PMID- 18201137
OWN - NLM
STAT- MEDLINE
DCOM- 20080415
LR  - 20211020
IS  - 1080-7683 (Print)
IS  - 1557-7732 (Electronic)
IS  - 1080-7683 (Linking)
VI  - 24
IP  - 1
DP  - 2008 Feb
TI  - Efficacy of a helicase-primase inhibitor in animal models of ocular herpes 
      simplex virus type 1 infection.
PG  - 34-42
LID - 10.1089/jop.2007.0084 [doi]
AB  - PURPOSE: The aim of this study was to evaluate the effect of BAY 57-1293, a 
      helicase-primase inhibitor, on herpes simplex virus type 1 (HSV-1) reactivation 
      in mice and its efficacy on established disease in rabbits. METHODS: BALB/c mice 
      latent for McKrae-strain HSV-1 were reactivated via heat stress, treated with BAY 
      57-1293, and their corneas were swabbed for virus or the trigeminal ganglia (TG) 
      obtained for quantification of viral DNA. New Zealand white rabbits were infected 
      and treated topically or orally in comparison with trifluridine or valacyclovir. 
      RESULTS: Oral BAY 57-1293 suppressed reactivation in HSV-1-infected mice and 
      reduced the viral load in TG up to four orders of magnitude. In the rabbits, the 
      therapeutic efficacies of topical BAY 57-1293 and trifluridine were similar. 
      Once-daily oral BAY 57-1293 was significantly more effective than valacyclovir 
      and as effective as twice a day topical trifluridine. CONCLUSIONS: BAY 57-1293 
      may be more effective than valacyclovir, without the cytotoxicity or potential 
      healing retardation seen with trifluridine. Oral BAY 57-1293 may be a substitute 
      for eye drops as an effective treatment for herpetic keratitis and might be 
      useful in treating stromal keratitis and iritis, as well as preventing 
      recurrences of ocular herpes.
FAU - Kaufman, Herbert E
AU  - Kaufman HE
AD  - Department of Ophthalmology, LSU Eye Center, Louisiana State University Health 
      Sciences Center in New Orleans, New Orleans, LA, USA. hkaufm@lsuhsc.edu
FAU - Varnell, Emily D
AU  - Varnell ED
FAU - Gebhardt, Bryan M
AU  - Gebhardt BM
FAU - Thompson, Hilary W
AU  - Thompson HW
FAU - Atwal, Ephraim
AU  - Atwal E
FAU - Rubsamen-Waigmann, Helga
AU  - Rubsamen-Waigmann H
FAU - Kleymann, Gerald
AU  - Kleymann G
LA  - eng
GR  - R01 EY002672/EY/NEI NIH HHS/United States
GR  - R01EY002672/EY/NEI NIH HHS/United States
GR  - P30 EY002377/EY/NEI NIH HHS/United States
GR  - P30EY002377/EY/NEI NIH HHS/United States
GR  - P30 EY002377-29/EY/NEI NIH HHS/United States
GR  - R01 EY002672-29/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Ocul Pharmacol Ther
JT  - Journal of ocular pharmacology and therapeutics : the official journal of the 
      Association for Ocular Pharmacology and Therapeutics
JID - 9511091
RN  - 0 (DNA, Viral)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (Sulfonamides)
RN  - 0 (Thiazoles)
RN  - 0 (Viral Proteins)
RN  - 07HQ1TJ4JE (pritelivir)
RN  - EC 2.7.7.- (DNA Primase)
RN  - EC 3.1.- (helicase-primase, Human herpesvirus 1)
RN  - EC 3.6.4.- (DNA Helicases)
SB  - IM
MH  - Animals
MH  - DNA Helicases/*antagonists & inhibitors
MH  - DNA Primase/*antagonists & inhibitors
MH  - DNA, Viral/chemistry
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Female
MH  - Heat Stress Disorders/virology
MH  - Herpesvirus 1, Human
MH  - Keratitis, Herpetic/*drug therapy
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Pyridines/*therapeutic use
MH  - Rabbits
MH  - Sulfonamides
MH  - Tears/virology
MH  - Thiazoles/*therapeutic use
MH  - Trigeminal Ganglion/virology
MH  - Viral Proteins/*antagonists & inhibitors
MH  - Virus Shedding/drug effects
PMC - PMC2365309
MID - NIHMS38198
EDAT- 2008/01/19 09:00
MHDA- 2008/04/16 09:00
PMCR- 2008/05/02
CRDT- 2008/01/19 09:00
PHST- 2008/01/19 09:00 [pubmed]
PHST- 2008/04/16 09:00 [medline]
PHST- 2008/01/19 09:00 [entrez]
PHST- 2008/05/02 00:00 [pmc-release]
AID - 10.1089/jop.2007.0084 [doi]
PST - ppublish
SO  - J Ocul Pharmacol Ther. 2008 Feb;24(1):34-42. doi: 10.1089/jop.2007.0084.